Joseph Hanna

Joseph Hanna

Auto-generated profile, based on publicly available information

Joseph Hanna

Department of Vascular Surgery, Royal Perth Hospital, Perth 6000, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Anz Journal of Surgery
Verified
Journal Article
Open access
ANAnantha Narayanan
Anantha Narayanan
JHJoseph Hanna
Joseph Hanna
AOAmy Okamura‐Kho
Amy Okamura‐Kho
JTJoshua Tesar
Joshua Tesar
ELEric T.A. Lim
Eric T.A. Lim
MKManar Khashram
Manar Khashram
BackgroundSecondary aorto-enteric fistulae (SAEF) are a rare, complex and life-threatening complication following aortic repair. Traditional treatment strategy has been with open aortic repair (OAR), with emergence of endovascular repair (EVAR) as a potentially viable initial treatment option. Controversy exists over optimal immediate and long-term management. MethodsAn observational, retrospective, multi-institutional study of patients who had been treated for SAEF between 2003 and 2020 was performed using a standardized database. Baseline characteristics, presenting features, microbiological, operative and post-operative variables were recorded. The primary outcome was short and mid-term mortality. Descriptive statistics, Kaplan-Meier, Cox age-adjusted survival analysis and binomial regression analysis were performed. ResultsThere were 47 patients treated for SAEF identified, with a median (range) age at presentation of 74 (48-93) and 7 were females. Initially, there were 24 (51%) treated with OAR, 15 (32%) with EVAR and 8 (17%) non-operatively. The 30-day and 1-year mortality for all cases that underwent intervention was 21% and 46% respectively. Age-adjusted survival analysis revealed no statistically significant difference in mortality in the EVAR-first group compared to the OAR-first group, HR 0.99 (95% CI 0.94-1.03, P = 0.61). ConclusionIn this study there was no difference in all-cause survival in patients who had OAR or EVAR as first line treatment for SAEF. In the acute setting, alongside broad-spectrum antimicrobial therapy, EVAR can be considered as an initial treatment for patients with SAEF, as a primary treatment or a bridge to definitive OAR.

8 June 2022 in Anz Journal of Surgery
Verified
Journal Article
Open access
A(Australian And New Zealand Vascular Trial Network (Anzvtn)
Australian And New Zealand Vascular Trial Network (Anzvtn)
SASarah Aitken
Sarah Aitken
BABernard Allard
Bernard Allard
NANishath Altaf
Nishath Altaf
NANoel Atkinson
Noel Atkinson
JWJackie Wong
Jackie Wong
Background Frailty predicts adverse perioperative outcomes and increased mortality in patients having vascular surgery. Frailty assessment is a potential tool to inform resource allocation, and shared decision-making about vascular surgery in the resource constrained COVID-19 pandemic environment. This cohort study describes the prevalence of frailty in patients having vascular surgery and the association between frailty, mortality and perioperative outcomes. Methods The COVID-19 Vascular Service in Australia (COVER-AU) prospective cohort study evaluates 30-day and six-month outcomes for consecutive patients having vascular surgery in 11 Australian vascular units, March-July 2020. The primary outcome was mortality, with secondary outcomes procedure-related outcomes and hospital utilization. Frailty was assessed using the nine-point visual Clinical Frailty Score, scores of 5 or more considered frail. Results Of the 917 patients enrolled, 203 were frail (22.1%). The 30 day and 6 month mortality was 2.0% (n = 20) and 5.9% (n = 35) respectively with no significant difference between frail and non-frail patients (OR 1.68, 95%CI 0.79-3.54). However, frail patients stayed longer in hospital, had more perioperative complications, and were more likely to be readmitted or have a reoperation when compared to non-frail patients. At 6 months, frail patients had twice the odds of major amputation compared to non-frail patients, after adjustment (OR 2.01; 95% CI 1.17-3.78), driven by a high rate of amputation during the period of reduced surgical activity. Conclusion Our findings highlight that older, frail patients, experience potentially preventable adverse outcomes and there is a need for targeted interventions to optimize care, especially in times of healthcare stress.

29 September 2023 in Anz Journal of Surgery
Verified
Journal Article
Closed access
DFDhanushke Fernando
Dhanushke Fernando
JHJoseph Hanna
Joseph Hanna
RCRyan Cohen
Ryan Cohen
JRJennifer Ryan
Jennifer Ryan

1 May 2014 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
JHJoseph S. Hanna
Joseph S. Hanna
VGVicente H. Gracias
Vicente H. Gracias

22 November 2022 in Anz Journal of Surgery
Verified
Journal Article
Closed access
JHJoseph Hanna
Joseph Hanna
BRBradley Reynolds
Bradley Reynolds
MCMatthew Chau
Matthew Chau
IAIvan Aw
Ivan Aw

13 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
JDJames Evan Dodd
James Evan Dodd
JHJoseph Hanna
Joseph Hanna
YGYann Gouëffic
Yann Gouëffic
MBMarianne Brodmann
Marianne Brodmann
KDKoen Deloose
Koen Deloose
Background: The BIO REACT study is designed to investigate the incremental value of Extravascular UltraSound (EVUS) added to conventional angiography, compared to conventional angiography only for the identification of Flow-Limiting Dissections (FLD) and to evaluate the safety and efficacy of the REsponse Adapted Combination Therapy (REACT) for the treatment of femoropopliteal lesions. Methods: The primary endpoints were the specificity and sensitivity of EVUS added to angiography for the detection of FLD. Secondary endpoints were primary patency of the REACT therapy within 12 months, fCD-TLR, freedom from MAE, major target limb amputations (mTLA) and survival rates within 24 months. Results: A total of 150 patients were included. EVUS added to angiography had an overall sensitivity of 29% and specificity of 93% for the detection of FLD. There was no PSVR cut-off offering a clinically acceptable trade-off between meaningful sensitivity and specificity values for the detection of FLD. At 12 months, treatment with the REACT resulted in primary patency and fCD-TLR of 81.6% and 94.3%, respectively. In addition, freedom from MAE was 94.3% at 12 months. At 24 months, the survival rate was 94.0%. No mTLA was reported up to the 24-month follow-up. Conclusions: The addition of DUS to angiography showed limited value for detecting FLD in femoropopliteal artery disease.